Introduction:

Overall survival of esophageal cancer patients remains low despite the therapeutic advances achieved in the last decades.

Objective:

Evaluate response to treatment and overall survival.

Methods:

An observational retrospective study was conducted of patients with advanced esophageal squamous cell carcinoma treated with nimotuzumab combined with chemoradiotherapy at the Clinical Oncology Service of Ameijeiras Hospital from January 2013 to June 2019 (n = 94). Association of variables was analyzed with the chi-square test, using a value of p < 0.05. Overall survival was evaluated with the Kaplan-Meier method, whereas the Log-Rank test was used to compare the curves.

Results:

Objective response and disease control rates were 64.9% and 83%, respectively. The chemotherapy scheme with cisplatin / fluorouracil was the most commonly applied. The variables with the greatest response and statistical significance were ECOG zero, skin color not white, radiation therapy ≥ 50 Gy and more than 14 doses of nimotuzumab. Median survival was 13.03 months (CI 95 % -10,9; 15,2), whereas the variables associated to a greater probability of survival were ECOG zero, chemotherapy dose > 75% of plan, radiation therapy ≥ 50 Gy, more than 14 doses of nimotuzumab, and achieving an objective response (p< 0.05). Only 5.8% of the patients presented toxicities classified as grades 3-5.

Conclusions:

In clinical practice conditions, this combination scheme achieved optimum objective response and survival rates with a good toxicity profile.

        · resumen en Español     · texto en Español     · Español ( pdf )